Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech Conference on December 8, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Organogenesis Holdings Inc. (Nasdaq: ORGO) will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology, and Medtech Conference on December 8, 2022. Held at The Fontainebleau Miami Beach, the event will feature panel discussions and 1x1 meetings with investors. This conference highlights the company’s focus on regenerative medicine, specifically in advanced wound care and surgical solutions. Organogenesis offers a range of bioactive and acellular biomaterials designed to meet diverse patient needs.
Details
News Market Reaction – ORGO
The recorded move for ORGO in the trading session of this news was -3.31%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference, which is being held at The Fontainebleau Miami Beach in Miami, FL on Thursday, December 8th. The conference consists of panel discussions and 1x1 meetings with investors. Management will participate in 1x1 meetings.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.